The aim of this work was the development and validation of a dissolution methodology for desloratadine-coated tablets by spectrophotometry on ultraviolet (UV). 0.1 M hydrochloric acid (HCl), pH 4.5-citrate buffer and pH 6.8 phosphate buffer were tested as dissolution medium. In addition, influences of apparatus, and rotation speed were evaluated. After an UV scan spectrum from 500 to 200 nm, to determine the maximum wavelength absorbance, samples were analyzed by UV visible spectrophotometric method. The parameters selected were 0.1 M HCl as dissolution medium, using paddles as apparatus at 50 rpm, with analysis at wavelength of 280 nm. The method was validated as per ICH guidelines, and the results showed that the dissolution methodology for desloratadine-coated tablets with 0.1 M HCl as dissolution medium, using paddles as apparatus at 50 rpm, with analysis at wavelength of 280 nm, with sampling points at 5, 10, 15 and 30 minutes is specific, linear, precise and accurate and could be applied for quality control of desloratadine tablets, since there is no official monograph.
Introduction
The dissolution tests allow to obtain information regarding the drug biological availability, being recognized also as an important tool to pharmaceutical companies on development and quality control, because helps on the research and development to guide the best formulation and ensure the lot-tolot quality of pharmaceutical dosage forms or for justifying postapproval product changes such as in the formulation and the manufacturing process [1] [2] [3] [4] [5] [6] [7] [8] [9] .
Dissolution is the only test that addresses product performance, therefore when developing a dissolution methodology, the knowledge related to solubility, permeability, and pharmacokinetics of the drug should be considered and the test must be capable to display the maximum discriminative profile and, also to allow to detect any deviation in quality standards initially proposed. The results from dissolution assays provides important information, including to establish in vitro/in vivo correlation 2, 7, [10] [11] [12] [13] [14] .
Methodology validation enables to know limitations and reliability of measurements performed. Per official codex, validation process is essential to ensure that the analytical method is suitable for the intended purpose, demonstrating reliable information through parameters such as specificity, linearity, accuracy and precision suitable for analysis 2, [15] [16] [17] [18] [19] [20] [21] .
Desloratadine, (8Chloro-11-piperidin-4-ylidene-6,11-diydro-5H-benzo [5, 6] Pró-Análise).
Methodology

Maximum wavelength absorption determination
Standard solutions with 5.56 μg/mL of desloratadine were prepared in the following medium: 0.1 M hydrochloric acid (HCl), pH 4.5-acetate buffer and pH 6.8 phosphate buffer. The samples were submitted to an UV scan spectrum between 500
to 200 nm to determinate desloratadine maximum wavelength absorption.
Dissolution test conditions
Dissolution testing of tablets was perfomed with the reference drug product (Desalex ® 5 mg), to define the method conditions.
Initially, to determinate the more discrimating dissolution medium, using paddles (USP apparatus II) at a stirring speed of 100 rpm, a volume of 900 mL of the following dissolution media, pre-heated to 37 °C ± 0.5 °C, were tested: 0.1 M HCl; pH 4. 
Validation
To demonstrate the method's suitability for use as a dissolution test, it was validated based on specificity, linearity, precision and accuracy parameter 16, 25 .
Specificity
Placebo samples of desloratadine, a mix of the excipients from the desloratadine reference drug tablets (Desalex ® ) were prepared in their usual compositions, according to literature 22, 26 . The placebo samples were transferred to different vessels (n=6) with 900 mL of 0.1 M HCl as dissolution medium at 37 °C ± 0.5 °C and stirred for 30 minutes at 50 rpm using a paddle (USP apparatus II). Aliquots of these solutions were filtered through a Millex ® filter and analyzed by the UV method (280 nm).
Linearity
Desloratadine stock solutions at 55.55 mg/mL, using 0. 
Precision
Precision was evaluated on two levels, repeatability and 
Results and Discussion
Dissolution method development
To determine which wavelength desloratadine shows UV absorption, an UV scan spectrum between 500-200 nm was performed. The results demonstrated that desloratadine showed a maximum absorption at 280 nm (Figure 1 ). However, both medium doesn't allowed total desloratadine dissolution, since the final drug dissolution was 74.76 % for pH 4.5-citrate buffer and 80.79 % for pH 6.8-phosphate buffer.
The dissolution medium where desloratadine showed complete dissolution, was 0.1 M HCl. Also, the dissolution profile at five points (5, 10, 15, 30 and 60 minutes) showed that the drug dissolved more than 85% in 15 minutes (Table 1 and Figure 2 ), classifying desloratadine as very rapidly dissolving drug. As desloratadine is an antihistamine drug used to relieve allergy symptoms, it must be ready to act in the body around 30 minutes after the drug intake 22 , a rapidly drug dissolution is required for immediate-release dosage forms 16, 26 . This results, corroborates with the fact that desloratadine is classified as a Class I drug (high solubility and high permeability) in Biopharmaceutical Classification System (BCS) 16 . The results indicated that 0.1 M HCl was selected as dissolution medium. Based on the results, is possible to determinate that a good dissolution method for desloratadine-coated tablets is using 900 mL 0.1 M HCl as dissolution medium with paddles at 50 rpm, samples withdraw at 5, 10, 15 and 30 minutes, filtered and analyzed at spectrophotometer at 280 nm.
Dissolution method validation
For the developed dissolution method meets the requirements of the analytical applications, ensuring results reliability, it should be validated.
To the results of specificity, analysis of desloratadine placebo solutions showed that the UV method suffer no interference from the formulation of the tablet evaluated, demonstrating to be specific ( Figure 4 ). Since there was no interference from the excipients with the selected wavelength (280 nm), UV can be used to quantify desloratadine. Analysis by UV are usually used in quality control of pharmaceuticals because most of drugs absorbed energy in UV region, and is a method, which does not require a complex or expensive equipment, and there is no need for toxic solvents 19 . In addition, by using UV method, results can be obtained faster, analysis is simpler and fewer solvents are used, making this valuable in routine analysis 16, 20, 26, 29 . The results from intra-day precision showed a relative standard deviation (RSD) of 0.82, 0.71 and 1.58 % from each of the three days and an RSD of 1.04 % for inter-day precision. As RSD values were lower than 5 %, the results indicated the good precision of this method 16, 18, 25 .
The accuracy of the analytical procedure, the accordance between the accepted value and the value found 
Conclusions
A discriminative dissolution method to evaluate desloratadine tablets was successfully developed and demonstrate to be an easy, fast and simple method. The conditions allowing dissolution determination were 900 mL of 0.1 M HCl as dissolution medium at 37.0 ± 0.5 ºC, using USP type II apparatus (paddles) at 50 rpm and analysis by spectrophotometric detection in a wavelength of 280 nm. The spectrophotometric method was validated and showed to be specific, linear, precise and accurate. The developed method is suitable for its purpose and could be applied in routine quality control of desloratadine tablets since there is no official monograph using spectrophotometric method for this drug in the pharmacopoeias.
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